Beta
Back to ABBV.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

ABBV Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q4'25, AbbVie's cash and short-term investments stood at $5.26B USD, reflecting a modest decline from $5.67B USD in Q3'25 and continuing a downward trajectory from the peak of $18.07B USD in Q1'24. In contrast, total debt remained substantial at $67.50B USD, down slightly from $68.74B USD in Q3'25 but still elevated compared to earlier periods. Over the period from Q1'23 to Q4'25, cash and short-term investments exhibited significant volatility, surging from $6.72B USD to a high of $18.07B USD in Q1'24 before steadily declining to $5.26B USD amid potential operational or investment outflows. Debt levels showed relative stability with a slight overall reduction from $62.09B USD in Q1'23 to $67.50B USD in Q4'25, though a notable spike to $74.00B USD occurred in Q1'24, highlighting periods of increased leverage that later moderated. This dynamic suggests improving debt management but persistent liquidity pressures, warranting monitoring for balance sheet sustainability.